INmune Bio Receives $8 Consensus Price Target from Analysts

The clinical-stage immunology company focuses on harnessing the innate immune system.

Mar. 15, 2026 at 10:10am

Got story updates? Submit your updates here. ›

INmune Bio, Inc. (NASDAQ:INMB) has earned a consensus 'Hold' recommendation from six ratings firms covering the company. The average 12-month price target among analysts is $8. The company's lead therapeutic candidate, XPro1595, is a selective inhibitor of soluble tumor necrosis factor designed to reduce chronic inflammation.

Why it matters

As a clinical-stage immunology company, INmune Bio's progress in developing treatments that harness the innate immune system is closely watched by investors and the broader healthcare industry. The consensus analyst rating and price target provide insight into Wall Street's current view of the company's prospects.

The details

Two analysts have rated INmune Bio's stock as a 'sell', two as 'hold', one as 'buy', and one as 'strong buy'. The company's shares have been trading in the $7-$8 range over the past year. Several institutional investors, including Royal Bank of Canada, Jane Street Group, and Rhumbline Advisers, have taken positions in INmune Bio.

  • INmune Bio reported its latest financial results on March 15, 2026.
  • The company provided an update on its lead drug candidate XPro1595 in February 2026.

The players

INmune Bio, Inc.

A clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat serious diseases.

XPro1595

INmune Bio's lead therapeutic candidate, a proprietary selective inhibitor of soluble tumor necrosis factor designed to reduce chronic inflammation.

Royal Bank of Canada

A major institutional investor that has increased its stake in INmune Bio.

Jane Street Group

A prominent institutional investor that has acquired a position in INmune Bio.

Rhumbline Advisers

An institutional investor that has added INmune Bio shares to its portfolio.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

As a clinical-stage company focused on innovative immunology treatments, INmune Bio's progress is closely watched by the investment community. The consensus analyst rating and price target suggest cautious optimism about the company's prospects, though continued development of its lead drug candidate will be crucial to driving future growth.